Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100
CONCLUSIONS: This exploratory analysis in advanced ROC did not find evidence for associations between gene expression signatures and outcomes of pembrolizumab. mIHC analysis suggests CD11c+ and CD11c+/MHCII-/CD163-/CD68- phenotypes representing myeloid cell populations may be associated with improved outcomes with pembrolizumab in advanced ROC.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02674061.PMID:37862791 | DOI:10.1016/j.ygyno.2023.09.012 (Source: Methods of Information in Medicine)
Source: Methods of Information in Medicine - October 20, 2023 Category: Information Technology Authors: Jonathan A Ledermann Ronnie Shapira-Frommer Alessandro D Santin Alla S Lisyanskaya Sandro Pignata Ignace Vergote Francesco Raspagliesi Gabe S Sonke Michael Birrer Diane M Provencher Jalid Sehouli Nicoletta Colombo Antonio Gonz ález-Martín Ana Oaknin P B Source Type: research
Pelvic irradiation for node-positive prostate cancer after prostatectomy: Long-term results of the prospective PLATIN-4 and PLATIN-5 trials
CONCLUSIONS: Salvage radiotherapy to the prostate bed and the pelvic lymphatic drainage combined with long-term ADT is a curative treatment option for patients with node-positive prostate cancer after RP with excellent infield disease control. PLNRT as field abutment after PBRT is feasible with long-term survival without suffering from high-grade toxicity.PMID:37863242 | DOI:10.1016/j.ijrobp.2023.10.009 (Source: Methods of Information in Medicine)
Source: Methods of Information in Medicine - October 20, 2023 Category: Information Technology Authors: C A Fink D Wegener L D Sauer A Lentz-Hommertgen J Liermann A C M üller D Zips J Debus K Herfarth S A Koerber Source Type: research
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100
CONCLUSIONS: This exploratory analysis in advanced ROC did not find evidence for associations between gene expression signatures and outcomes of pembrolizumab. mIHC analysis suggests CD11c+ and CD11c+/MHCII-/CD163-/CD68- phenotypes representing myeloid cell populations may be associated with improved outcomes with pembrolizumab in advanced ROC.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02674061.PMID:37862791 | DOI:10.1016/j.ygyno.2023.09.012 (Source: Methods of Information in Medicine)
Source: Methods of Information in Medicine - October 20, 2023 Category: Information Technology Authors: Jonathan A Ledermann Ronnie Shapira-Frommer Alessandro D Santin Alla S Lisyanskaya Sandro Pignata Ignace Vergote Francesco Raspagliesi Gabe S Sonke Michael Birrer Diane M Provencher Jalid Sehouli Nicoletta Colombo Antonio Gonz ález-Martín Ana Oaknin P B Source Type: research
Pelvic irradiation for node-positive prostate cancer after prostatectomy: Long-term results of the prospective PLATIN-4 and PLATIN-5 trials
CONCLUSIONS: Salvage radiotherapy to the prostate bed and the pelvic lymphatic drainage combined with long-term ADT is a curative treatment option for patients with node-positive prostate cancer after RP with excellent infield disease control. PLNRT as field abutment after PBRT is feasible with long-term survival without suffering from high-grade toxicity.PMID:37863242 | DOI:10.1016/j.ijrobp.2023.10.009 (Source: Methods of Information in Medicine)
Source: Methods of Information in Medicine - October 20, 2023 Category: Information Technology Authors: C A Fink D Wegener L D Sauer A Lentz-Hommertgen J Liermann A C M üller D Zips J Debus K Herfarth S A Koerber Source Type: research
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100
CONCLUSIONS: This exploratory analysis in advanced ROC did not find evidence for associations between gene expression signatures and outcomes of pembrolizumab. mIHC analysis suggests CD11c+ and CD11c+/MHCII-/CD163-/CD68- phenotypes representing myeloid cell populations may be associated with improved outcomes with pembrolizumab in advanced ROC.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02674061.PMID:37862791 | DOI:10.1016/j.ygyno.2023.09.012 (Source: Methods of Information in Medicine)
Source: Methods of Information in Medicine - October 20, 2023 Category: Information Technology Authors: Jonathan A Ledermann Ronnie Shapira-Frommer Alessandro D Santin Alla S Lisyanskaya Sandro Pignata Ignace Vergote Francesco Raspagliesi Gabe S Sonke Michael Birrer Diane M Provencher Jalid Sehouli Nicoletta Colombo Antonio Gonz ález-Martín Ana Oaknin P B Source Type: research
Pelvic irradiation for node-positive prostate cancer after prostatectomy: Long-term results of the prospective PLATIN-4 and PLATIN-5 trials
CONCLUSIONS: Salvage radiotherapy to the prostate bed and the pelvic lymphatic drainage combined with long-term ADT is a curative treatment option for patients with node-positive prostate cancer after RP with excellent infield disease control. PLNRT as field abutment after PBRT is feasible with long-term survival without suffering from high-grade toxicity.PMID:37863242 | DOI:10.1016/j.ijrobp.2023.10.009 (Source: Methods of Information in Medicine)
Source: Methods of Information in Medicine - October 20, 2023 Category: Information Technology Authors: C A Fink D Wegener L D Sauer A Lentz-Hommertgen J Liermann A C M üller D Zips J Debus K Herfarth S A Koerber Source Type: research
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100
CONCLUSIONS: This exploratory analysis in advanced ROC did not find evidence for associations between gene expression signatures and outcomes of pembrolizumab. mIHC analysis suggests CD11c+ and CD11c+/MHCII-/CD163-/CD68- phenotypes representing myeloid cell populations may be associated with improved outcomes with pembrolizumab in advanced ROC.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02674061.PMID:37862791 | DOI:10.1016/j.ygyno.2023.09.012 (Source: Methods of Information in Medicine)
Source: Methods of Information in Medicine - October 20, 2023 Category: Information Technology Authors: Jonathan A Ledermann Ronnie Shapira-Frommer Alessandro D Santin Alla S Lisyanskaya Sandro Pignata Ignace Vergote Francesco Raspagliesi Gabe S Sonke Michael Birrer Diane M Provencher Jalid Sehouli Nicoletta Colombo Antonio Gonz ález-Martín Ana Oaknin P B Source Type: research
Pelvic irradiation for node-positive prostate cancer after prostatectomy: Long-term results of the prospective PLATIN-4 and PLATIN-5 trials
CONCLUSIONS: Salvage radiotherapy to the prostate bed and the pelvic lymphatic drainage combined with long-term ADT is a curative treatment option for patients with node-positive prostate cancer after RP with excellent infield disease control. PLNRT as field abutment after PBRT is feasible with long-term survival without suffering from high-grade toxicity.PMID:37863242 | DOI:10.1016/j.ijrobp.2023.10.009 (Source: Methods of Information in Medicine)
Source: Methods of Information in Medicine - October 20, 2023 Category: Information Technology Authors: C A Fink D Wegener L D Sauer A Lentz-Hommertgen J Liermann A C M üller D Zips J Debus K Herfarth S A Koerber Source Type: research
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100
CONCLUSIONS: This exploratory analysis in advanced ROC did not find evidence for associations between gene expression signatures and outcomes of pembrolizumab. mIHC analysis suggests CD11c+ and CD11c+/MHCII-/CD163-/CD68- phenotypes representing myeloid cell populations may be associated with improved outcomes with pembrolizumab in advanced ROC.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02674061.PMID:37862791 | DOI:10.1016/j.ygyno.2023.09.012 (Source: Methods of Information in Medicine)
Source: Methods of Information in Medicine - October 20, 2023 Category: Information Technology Authors: Jonathan A Ledermann Ronnie Shapira-Frommer Alessandro D Santin Alla S Lisyanskaya Sandro Pignata Ignace Vergote Francesco Raspagliesi Gabe S Sonke Michael Birrer Diane M Provencher Jalid Sehouli Nicoletta Colombo Antonio Gonz ález-Martín Ana Oaknin P B Source Type: research
Pelvic irradiation for node-positive prostate cancer after prostatectomy: Long-term results of the prospective PLATIN-4 and PLATIN-5 trials
CONCLUSIONS: Salvage radiotherapy to the prostate bed and the pelvic lymphatic drainage combined with long-term ADT is a curative treatment option for patients with node-positive prostate cancer after RP with excellent infield disease control. PLNRT as field abutment after PBRT is feasible with long-term survival without suffering from high-grade toxicity.PMID:37863242 | DOI:10.1016/j.ijrobp.2023.10.009 (Source: Methods of Information in Medicine)
Source: Methods of Information in Medicine - October 20, 2023 Category: Information Technology Authors: C A Fink D Wegener L D Sauer A Lentz-Hommertgen J Liermann A C M üller D Zips J Debus K Herfarth S A Koerber Source Type: research
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100
CONCLUSIONS: This exploratory analysis in advanced ROC did not find evidence for associations between gene expression signatures and outcomes of pembrolizumab. mIHC analysis suggests CD11c+ and CD11c+/MHCII-/CD163-/CD68- phenotypes representing myeloid cell populations may be associated with improved outcomes with pembrolizumab in advanced ROC.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02674061.PMID:37862791 | DOI:10.1016/j.ygyno.2023.09.012 (Source: Methods of Information in Medicine)
Source: Methods of Information in Medicine - October 20, 2023 Category: Information Technology Authors: Jonathan A Ledermann Ronnie Shapira-Frommer Alessandro D Santin Alla S Lisyanskaya Sandro Pignata Ignace Vergote Francesco Raspagliesi Gabe S Sonke Michael Birrer Diane M Provencher Jalid Sehouli Nicoletta Colombo Antonio Gonz ález-Martín Ana Oaknin P B Source Type: research
Pelvic irradiation for node-positive prostate cancer after prostatectomy: Long-term results of the prospective PLATIN-4 and PLATIN-5 trials
CONCLUSIONS: Salvage radiotherapy to the prostate bed and the pelvic lymphatic drainage combined with long-term ADT is a curative treatment option for patients with node-positive prostate cancer after RP with excellent infield disease control. PLNRT as field abutment after PBRT is feasible with long-term survival without suffering from high-grade toxicity.PMID:37863242 | DOI:10.1016/j.ijrobp.2023.10.009 (Source: Methods of Information in Medicine)
Source: Methods of Information in Medicine - October 20, 2023 Category: Information Technology Authors: C A Fink D Wegener L D Sauer A Lentz-Hommertgen J Liermann A C M üller D Zips J Debus K Herfarth S A Koerber Source Type: research
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100
CONCLUSIONS: This exploratory analysis in advanced ROC did not find evidence for associations between gene expression signatures and outcomes of pembrolizumab. mIHC analysis suggests CD11c+ and CD11c+/MHCII-/CD163-/CD68- phenotypes representing myeloid cell populations may be associated with improved outcomes with pembrolizumab in advanced ROC.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02674061.PMID:37862791 | DOI:10.1016/j.ygyno.2023.09.012 (Source: Methods of Information in Medicine)
Source: Methods of Information in Medicine - October 20, 2023 Category: Information Technology Authors: Jonathan A Ledermann Ronnie Shapira-Frommer Alessandro D Santin Alla S Lisyanskaya Sandro Pignata Ignace Vergote Francesco Raspagliesi Gabe S Sonke Michael Birrer Diane M Provencher Jalid Sehouli Nicoletta Colombo Antonio Gonz ález-Martín Ana Oaknin P B Source Type: research
Pelvic irradiation for node-positive prostate cancer after prostatectomy: Long-term results of the prospective PLATIN-4 and PLATIN-5 trials
CONCLUSIONS: Salvage radiotherapy to the prostate bed and the pelvic lymphatic drainage combined with long-term ADT is a curative treatment option for patients with node-positive prostate cancer after RP with excellent infield disease control. PLNRT as field abutment after PBRT is feasible with long-term survival without suffering from high-grade toxicity.PMID:37863242 | DOI:10.1016/j.ijrobp.2023.10.009 (Source: Methods of Information in Medicine)
Source: Methods of Information in Medicine - October 20, 2023 Category: Information Technology Authors: C A Fink D Wegener L D Sauer A Lentz-Hommertgen J Liermann A C M üller D Zips J Debus K Herfarth S A Koerber Source Type: research
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100
CONCLUSIONS: This exploratory analysis in advanced ROC did not find evidence for associations between gene expression signatures and outcomes of pembrolizumab. mIHC analysis suggests CD11c+ and CD11c+/MHCII-/CD163-/CD68- phenotypes representing myeloid cell populations may be associated with improved outcomes with pembrolizumab in advanced ROC.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02674061.PMID:37862791 | DOI:10.1016/j.ygyno.2023.09.012 (Source: Methods of Information in Medicine)
Source: Methods of Information in Medicine - October 20, 2023 Category: Information Technology Authors: Jonathan A Ledermann Ronnie Shapira-Frommer Alessandro D Santin Alla S Lisyanskaya Sandro Pignata Ignace Vergote Francesco Raspagliesi Gabe S Sonke Michael Birrer Diane M Provencher Jalid Sehouli Nicoletta Colombo Antonio Gonz ález-Martín Ana Oaknin P B Source Type: research
